Minerva Neurosciences (NERV) Competitors $1.64 -0.01 (-0.61%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, VTVT, and APLTShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), vTv Therapeutics (VTVT), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences Aadi Bioscience Atara Biotherapeutics RenovoRx vTv Therapeutics Applied Therapeutics Kalaris Therapeutics (NASDAQ:KLRS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Which has more volatility and risk, KLRS or NERV? Kalaris Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. Is KLRS or NERV more profitable? Minerva Neurosciences' return on equity of -20.68% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -62.08% -54.69% Minerva Neurosciences N/A -20.68%15.73% Which has higher valuation and earnings, KLRS or NERV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/AMinerva NeurosciencesN/AN/A$1.44M$0.822.00 Do analysts rate KLRS or NERV? Minerva Neurosciences has a consensus target price of $5.00, indicating a potential upside of 204.88%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in KLRS or NERV? 66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 75.0% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor KLRS or NERV? In the previous week, Minerva Neurosciences had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Minerva Neurosciences' score of -0.40 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kalaris Therapeutics Neutral Minerva Neurosciences Neutral SummaryMinerva Neurosciences beats Kalaris Therapeutics on 6 of the 10 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.54M$2.37B$5.44B$8.92BDividend YieldN/A1.78%5.22%4.00%P/E Ratio2.008.8927.2520.05Price / SalesN/A666.36426.50117.27Price / Cash7.9021.7726.2128.59Price / Book-0.454.507.925.57Net Income$1.44M$31.26M$3.17B$248.56M7 Day Performance-4.65%5.60%4.48%7.44%1 Month Performance-10.33%5.93%2.80%8.43%1 Year Performance-47.10%8.83%35.04%21.72% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.9419 of 5 stars$1.64-0.6%$5.00+204.9%-45.2%$11.54MN/A2.009News CoverageGap UpKLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110Positive NewsGap UpBLUEbluebird bio2.1097 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520ADVMAdverum Biotechnologies4.0895 of 5 stars$2.15-7.3%$23.80+1,007.0%-65.4%$48.47M$1M-0.34190VRCAVerrica Pharmaceuticals3.6153 of 5 stars$0.53+1.4%$8.00+1,409.1%-91.0%$48.34M$7.57M-0.4440DTILPrecision BioSciences4.5046 of 5 stars$4.20-2.3%$47.00+1,019.0%-52.4%$47.68M$68.70M-2.09200AADIAadi Bioscience0.6437 of 5 stars$1.93+1.6%$1.67-13.6%+49.6%$47.67M$25.07M-0.8540ATRAAtara Biotherapeutics4.1086 of 5 stars$7.72-3.0%$17.75+129.9%-3.3%$47.45M$128.94M-2.08330Gap DownRNXTRenovoRx2.873 of 5 stars$1.32+2.7%$7.25+451.3%+18.9%$46.81M$40K-3.296Positive NewsVTVTvTv Therapeutics1.9217 of 5 stars$15.00+3.5%$35.50+136.7%-23.0%$46.29M$1.02M-4.989APLTApplied Therapeutics3.7932 of 5 stars$0.31-3.9%$6.10+1,860.8%-92.5%$45.84M$460K-0.7230News CoverageGap Up Related Companies and Tools Related Companies Kalaris Therapeutics Alternatives bluebird bio Alternatives Adverum Biotechnologies Alternatives Verrica Pharmaceuticals Alternatives Precision BioSciences Alternatives Aadi Bioscience Alternatives Atara Biotherapeutics Alternatives RenovoRx Alternatives vTv Therapeutics Alternatives Applied Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
